Insider Purchases: Inside the Buy

Tag: healthcare stocks

Centene stock represented as a patient monitor line bouncing off the lows, with a stethoscope over a red SALE tag — symbolizing insider buying amid financial troubles.

Centene (CNC): CEO Buys at $25, Earnings Bleed Red, and the Stock’s on Life Support — Bargain or Bust?

Centene (CNC) just got a shot in the arm from its CEO and a director buying nearly $740K worth of stock near decade lows. But with Q2 earnings bleeding red, rising Medicaid costs, and valuation sliced in half, is this a bargain-bin opportunity or just a patient in the ICU?

Read entire article

Tags: Centene, CEO insider buying, CEO Stock Purchase, CNC, Director Insider Buying, Funanc1al Insider Series, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInsiderSeries, Funanc1alInsights, Funanc1alStocks, Healthcare Stocks, High Risk High Reward, Insider Buying, Institutional Ownership, Medicaid, Medicare, Value Investing
A colorful digital illustration featuring Moderna's logo (MRNA) with a rising stock chart, symbolizing the biotech company's potential growth and innovation in gene-based therapies.

Moderna (MRNA): The Biotech Rollercoaster – Will This Gene Editor Reach the Top? 🎢💉

Moderna (MRNA) might be on the downhill since its peak in 2021, but its remarkable mRNA platform is fueling new therapeutic breakthroughs. With strong insider bets, a healthy pipeline, and institutional backing, Moderna could be an intriguing long-term play for investors. However, risks like intense competition and COVID sales deceleration remain. Should you bet on Moderna’s future or stay on the sidelines? Here’s what you need to know.

Read entire article

Tags: Biotech Investments, Biotech Stocks, Biotechnology, Biotechnology Innovation, COVID Vaccine, Gene Editing, healthcare stocks, Insider Purchases, Investment Insights, Moderna, Moderna CEO, mRNA, Paul Sagan, pharmaceutical stocks, Stephane Bancel